MetaVia Q2 net loss widens on higher R&D spending
MetaVia Inc expected to post a loss of 82 cents a share - Earnings Preview
Brief: Biostem Technologies Announces Appointment Of Three New Members To Its Board Of Directors
MetaVia Q1 net loss widens slightly as expenses rise
U.S. STOCKS ON THE MOVE-Organon, CoreWeave, Angel Studios
U.S. STOCKS ON THE MOVE- Sezzle, ServiceNow, Shake Shack
U.S. STOCKS ON THE MOVE-MetaVia, LifeMD, Nike
MetaVia rises as it starts higher-dose obesity drug study
Brief: Metavia Doses The First Patient In Higher-Dose Phase 1 Study Of Da-1726, Its Glp-1 And Glucagon Dual Agonist For The Treatment Of Obesity
Brief: Metavia Reports Year End 2025 Financial Results And Provides Corporate Update
Advisory: Alert wrongly tagged to Metavia Inc withdrawn
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies
U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist
MetaVia rises on regulatory nod to begin early-stage obesity trial
Brief: Metavia Advances Glp-1-Based Obesity Program With Irb Approval For Higher-Dose Phase 1 Studies Of Da-1726, A Glp-1 And Glucagon Dual Agonist Demonstrating Best-In-Class Potential For Weight Loss And Glucose Control
U.S. STOCKS ON THE MOVE-Moderna, Mohawk,
U.S. STOCKS ON THE MOVE-Moderna, Mohawk
Brief: Metavia Builds Comprehensive Global Patent Protection For Da-1726, Securing Exclusive Rights To Novel Obesity And Metabolic Therapy